Stereotactic ablative radiotherapy for malignant mediastinal and hilar lymphadenopathy: a systematic review.

ABSTRACT:

Background

Stereotactic ablative radiotherapy (SABR) safety and efficacy for mediastinal and hilar lymphadenopathy (MHL) is not yet established, given its potential for toxicity due to the proximity to esophagus and proximal bronchial tree (PBT). This review summarized current reported outcomes of MHL SABR.

Methods

This systematic review, based on the PRISMA guidelines, was performed using MEDLINE® (PubMed®), EMBASE and Cochrane Library databases from inception until December 2018. Studies reporting outcomes from SABR specifically for MHL from all primary malignancies were included. Non- English studies, guidelines, reviews, non-peer reviewed correspondences were excluded. Only the most recent publication and/or largest cohort from a single institution would be included for

SUBMITTER: Tjong MC 

PROVIDER: S-EPMC7330368 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature